Indian Pharma sees robust growth of 51.5 percent in April sales: AIOCD-AWACS Report

New Delhi: The performance of the Indian Pharmaceutical Market (IPM) in April has portrayed a positive outlook for the Indian pharmaceutical industry with a robust growth of 51.5 percent for the month of April 21, compared to 10.3 per cent for the month of March 2021, as per the data from market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).

According to the AIOCD AWACS report, this rapid growth in Indian Pharmaceutical Market (IPM) is based on three reasons:-

• Correction to the dip that was seen in Apr 2020

• The pharma industry has been well prepared for production and distribution exigencies that are expected during lockdown. If one looks at the growth drivers, volume growth has a lion's share in the growth of the market.

• The second wave of Covid has increased sales of drugs that play a direct/indirect role in treatment.

Further, the report revealed that anti-infectives have shown a growth of 134% and nutritionals have shown a growth of 76% while Cardiac registered a monthly growth of 26.9% in April 2021 while Anti-diabetic sales increased by only a 13.1% growth rate in April 2021.

The report further included that gastrointestinal drugs grew at a faster rate of 56.8% in April 2021 compared to 21.6% per cent in March 2021. The Respiratory domain, meanwhile, grew at a faster pace of 49.7% in April 2021 compared to 22.2% in March 2021.

Furthermore, pain/analgesics, neuro/CNS drugs, gynecological, antineoplastic, hormones, and opthal/otologicals grew at 64.2%, 21.3% ,47.0% ,38.7% ,54.5% ,37.6% respectively.

Considering the market performance, the study said, "Companies operating in Covid treatment therapy segments have gained substantially through bumper sales for the month."

However, based on sales results, Glenmark's Fabiflu, an antiviral medication Favipiravir that is widely prescribed in Covid 19, dominated the list of highest-selling products this month, followed by USV Private Limited's Glycomet GP, a fixed dosage mixture of Glimepride and Metformin, and Abbott's Mixtard, a human premix Insulin.

Cipla topped the top ten list with a MAT corporate growth of 13.6 percent in the month of April 21, with bonus units at full value, according to the report, followed by Intas with a MAT corporate growth of 8.2 percent.

Similarly, Glenmark had the highest MAT corporate growth percentage of approximately 29 percent among the 11 to 25 ranked corporates in the month of April 21, accompanied by Himalaya with a MAT corporate growth percentage of 18.55 percent.